Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JEFFREY J SENFIELD

Allopathic & Osteopathic Physicians Internal Medicine Clinical Cardiac Electrophysiology

NPI
1871727073
CMS profile
176240
Location
GREENVILLE, SC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$26,138.99

172 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

By paying entity

PY2024 · entire year · sorted by reported total

Page 3 of 4; records 101–150 of 172 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JEFFREY J SENFIELD

NPI 1871727073 · CMS profile ID 176240

Allopathic & Osteopathic Physicians / Internal Medicine / Clinical Cardiac Electrophysiology

GREENVILLE, SC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 4; records 101–150 of 172 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1871727073?year=2024&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JEFFREY J SENFIELD, NPI 1871727073, CMS profile ID 176240. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 172 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1871727073?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). JEFFREY J SENFIELD, NPI 1871727073, CMS profile ID 176240. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 172 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1871727073?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
JEFFREY J SENFIELD, NPI 1871727073, CMS profile ID 176240, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 4; records 101–150 of 172 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1871727073?year=2024&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

172 matching records · $26,138.99 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 172 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 172.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
CARDIVA MEDICAL, INC. $33.9705/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143861106 CMS
BIOTRONIK INC. $3.0505/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145796193 CMS
BIOTRONIK INC. $66.7005/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145796249 CMS
Impulse Dynamics (USA) Inc. $182.8605/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1100407461 CMS
BIOTRONIK INC. $9.4705/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145796187 CMS
BIOTRONIK INC. $61.5205/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145796189 CMS
Impulse Dynamics (USA) Inc. $175.7305/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1100407098 CMS
Impulse Dynamics (USA) Inc. $26.5205/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1100407089 CMS
Impulse Dynamics (USA) Inc. $59.7605/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1100407093 CMS
Medtronic, Inc. $166.9205/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1119526152 CMS
BIOTRONIK INC. $126.5605/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145796185 CMS
Impulse Dynamics (USA) Inc. $5.7905/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1100407085 CMS
Medtronic, Inc. $14.4505/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1119526154 CMS
Impulse Dynamics (USA) Inc. $148.4105/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1100407081 CMS
CARDIVA MEDICAL, INC. $25.9605/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143861104 CMS
ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $17.9505/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1080624999 CMS
Abbott Laboratories $3.4804/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1125315474 CMS
Boston Scientific Corporation $17.0404/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1092384016 CMS
SANOFI-AVENTIS U.S. LLC $121.6004/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139806608 CMS
SANOFI-AVENTIS U.S. LLC $4,255.0004/25/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139806658 CMS
ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $7.2004/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1080624975 CMS
ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $1,500.0004/24/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1085840052 CMS
BIOTRONIK INC. $2,000.0004/18/2024 Compensation for serving as faculty or as a speaker for a medical education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145796267 CMS
BIOTRONIK INC. $81.9904/18/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145796281 CMS
Biosense Webster, Inc. $144.0104/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1077719382 CMS
Impulse Dynamics (USA) Inc. $112.8304/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1100407076 CMS
Medtronic, Inc. $2.6604/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1119526148 CMS
Boston Scientific Corporation $144.0604/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1092383994 CMS
ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $14.8104/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1080624963 CMS
ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $17.3304/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1080624965 CMS
iRhythm Technologies, Inc. $4.7304/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1154056244 CMS
CARDIVA MEDICAL, INC. $23.5304/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143861102 CMS
Impulse Dynamics (USA) Inc. $38.9704/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1100407072 CMS
Medtronic, Inc. $38.9803/31/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1119526150 CMS
CARDIVA MEDICAL, INC. $16.6303/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143861100 CMS
CARDIVA MEDICAL, INC. $39.4903/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143861098 CMS
Impulse Dynamics (USA) Inc. $15.3403/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1100407115 CMS
ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $750.0003/13/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1085840050 CMS
ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $20.3603/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1080624879 CMS
Medtronic, Inc. $14.1403/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1119526146 CMS
BIOTRONIK INC. $18.0002/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145796295 CMS
Impulse Dynamics (USA) Inc. $1.4102/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1100407110 CMS
ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $22.0702/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1080624859 CMS
ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $90.0702/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1080624853 CMS
Boston Scientific Corporation $41.2302/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1092383980 CMS
CARDIVA MEDICAL, INC. $25.9602/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143861096 CMS
Impulse Dynamics (USA) Inc. $15.9802/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1100407106 CMS
BIOTRONIK INC. $16.1402/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145796293 CMS
Medtronic, Inc. $16.3302/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1119526144 CMS
Boston Scientific Corporation $102.0002/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1092383990 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $10,012.18 212
PY2020 $4,141.24 90
PY2021 $7,062.34 168
PY2022 $8,714.42 136
PY2023 $19,932.34 175
PY2024 $26,138.99 172
PY2025 $12,132.36 182

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $66,978.00 20
PY2024 Principal investigator $151,349.90 30
PY2023 Principal investigator $29,897.00 3
PY2022 Principal investigator $8,924.74 22
PY2021 Principal investigator $19,681.61 36
PY2020 Recipient $300.00 1
PY2020 Principal investigator $66,872.00 23
PY2019 Principal investigator $85,188.00 429

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

20 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Janssen Research & Development, LLC $1,200.00 12/24/2025 Non-covered Recipient Entity
Bon Secours Mercy Hlth Syst
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175257503
Principal investigator 1 Janssen Research & Development, LLC $3,010.00 12/12/2025 Non-covered Recipient Entity
Bon Secours Mercy Hlth Syst
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175256763
Principal investigator 1 Janssen Research & Development, LLC $6,843.00 11/19/2025 Non-covered Recipient Entity
Bon Secours Mercy Hlth Syst
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175256726
Principal investigator 1 Janssen Research & Development, LLC $5,909.00 11/07/2025 Non-covered Recipient Entity
Bon Secours Mercy Hlth Syst
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175256737
Principal investigator 1 Janssen Research & Development, LLC $741.00 11/05/2025 Non-covered Recipient Entity
Bon Secours Mercy Hlth Syst
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175257519
Principal investigator 1 Janssen Research & Development, LLC $231.00 11/03/2025 Non-covered Recipient Entity
Bon Secours Mercy Hlth Syst
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175257511
Principal investigator 1 Janssen Research & Development, LLC $6,000.00 10/17/2025 Non-covered Recipient Entity
Bon Secours Mercy Hlth Syst
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175257108
Principal investigator 1 Janssen Research & Development, LLC $1,206.00 10/02/2025 Non-covered Recipient Entity
Bon Secours Mercy Hlth Syst
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175257766
Principal investigator 1 Janssen Research & Development, LLC $356.00 09/25/2025 Non-covered Recipient Entity
Bon Secours Mercy Hlth Syst
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175256959
Principal investigator 1 Janssen Research & Development, LLC $2,323.00 09/19/2025 Non-covered Recipient Entity
Bon Secours Mercy Hlth Syst
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175256801
Principal investigator 1 Janssen Research & Development, LLC $4,580.00 08/25/2025 Non-covered Recipient Entity
Bon Secours Mercy Hlth Syst
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175257400
Principal investigator 1 Janssen Research & Development, LLC $5,931.00 07/23/2025 Non-covered Recipient Entity
Bon Secours Mercy Hlth Syst
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175257474
Principal investigator 1 Janssen Research & Development, LLC $231.00 06/23/2025 Non-covered Recipient Entity
Bon Secours Mercy Hlth Syst
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175257311
Principal investigator 1 Janssen Research & Development, LLC $4,372.00 06/20/2025 Non-covered Recipient Entity
Bon Secours Mercy Hlth Syst
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175256816
Principal investigator 1 Janssen Research & Development, LLC $6,964.00 05/21/2025 Non-covered Recipient Entity
Bon Secours Mercy Hlth Syst
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175257541
Principal investigator 1 Janssen Research & Development, LLC $3,983.00 04/23/2025 Non-covered Recipient Entity
Bon Secours Mercy Hlth Syst
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175256864
Principal investigator 1 Janssen Research & Development, LLC $844.00 04/16/2025 Non-covered Recipient Entity
Bon Secours Mercy Hlth Syst
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175257435
Principal investigator 1 Janssen Research & Development, LLC $1,806.00 03/21/2025 Non-covered Recipient Entity
Bon Secours Mercy Hlth Syst
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175257710
Principal investigator 1 Janssen Research & Development, LLC $6,431.00 02/19/2025 Non-covered Recipient Entity
Bon Secours Mercy Hlth Syst
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175257271
Principal investigator 1 Janssen Research & Development, LLC $4,017.00 01/22/2025 Non-covered Recipient Entity
Bon Secours Mercy Hlth Syst
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175256929